Hartmut Döhner
哈特穆特·德纳
MD
Director, Department of Internal Medicine III (Hematology, Oncology, Palliative Medicine)内科三科（血液、肿瘤、姑息治疗）主任
👥Biography 个人简介
Hartmut Döhner is a world authority on AML molecular genetics and risk stratification. He has led the European LeukemiaNet (ELN) classification efforts and co-developed pivotal prognostic frameworks and targeted therapy trials that define modern AML management.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
ELN AML Classification
Architect of the ELN 2010, 2017, and 2022 AML genetic risk classifications, providing globally adopted frameworks for prognosis and treatment decision-making.
Targeted Therapy Trials
Led international trials including RATIFY, establishing midostaurin as the first targeted agent to improve survival in FLT3-mutated AML patients receiving intensive chemotherapy.
Representative Works 代表性著作
Diagnosis and Management of AML in Adults: 2022 ELN Recommendations
Blood (2022)
Updated ELN guidelines incorporating molecular profiling, MRD assessment, and targeted therapies as the global standard for AML classification and therapy.
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
New England Journal of Medicine (2017)
RATIFY trial results demonstrating midostaurin improved overall survival in FLT3-mutated AML, leading to FDA and EMA approval.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 哈特穆特·德纳 的研究动态
Follow Hartmut Döhner's research updates
留下邮箱，当我们发布与 Hartmut Döhner（University Hospital Ulm）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment